Search

Displaying results 8251 - 8260 of 10000 in total
  1. Pathway

    Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-O(9S,10R)/20:0)

    smpdb.ca/view/SMP0127289
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine · Pyrophosphoric acid
  2. Pathway

    Phosphatidylethanolamine Biosynthesis PE(18:2(10E,12Z)+=O(9)/18:0)

    smpdb.ca/view/SMP0127300
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine · Pyrophosphoric acid
  3. Pathway

    Phosphatidylethanolamine Biosynthesis PE(18:2(10E,12Z)+=O(9)/22:0)

    smpdb.ca/view/SMP0127302
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine · Pyrophosphoric acid
  4. Pathway

    Phosphatidylethanolamine Biosynthesis PE(20:0/18:2(10E,12Z)+=O(9))

    smpdb.ca/view/SMP0127324
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine · Pyrophosphoric acid
  5. Pathway

    Phosphatidylethanolamine Biosynthesis PE(22:0/18:1(12Z)-O(9S,10R))

    smpdb.ca/view/SMP0127530
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine · Pyrophosphoric acid
  6. Drug

    Theobromine

    go.drugbank.com/drugs/DB01412
    Investigational

    It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9) … It has a weaker diuretic activity than theophylline and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system.

  7. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    It is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.

  8. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM.

  9. Drug

    Omega-6 fatty acids

    go.drugbank.com/drugs/DB13168
    InvestigationalNutraceutical

    Arachidonic acid, which is a main precursor of eicosanoids, is an example of omega-6 (n-6) polyunsaturated fatty acids. Vegetable oil is a major dietary sources of omega-6 fatty acids. … Omega-6 fatty acids are polyunsaturated fatty acids with a final carbon-carbon double bond in the n-6 position, that is, the sixth bond, counting from the methyl end.

    Synonyms: Omega 6 acids, n-6 fatty acids
  10. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    [A263973] It is used to treat anemia in patients with myelodysplastic syndromes (MDS), a group of hematologic disorders characterized by ineffective hematopoiesis, peripheral cytopenia, abnormal marrow … [erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors